$CYNO (Cynosure, Inc.)

$CYNO {{ '2016-09-13T15:02:32+0000' | timeago}} • Announcement

Medical devices company $CYNO said Stephen J. Webber will join the company on October 10, 2016 as EVP. Mr. Webber will then become CFO and Chief Accounting Officer effective upon the filing of $CYNO's Form 10-Q in November. He will succeed Timothy W. Baker, who will be retiring from the company.

$LMNX {{ '2017-07-24T14:45:10+0000' | timeago}} • Announcement

$LMNX has received FDA clearance for its Aries C. difficile Assay, a method for rapid detection of toxigenic agents. The Aries system is designed to run in multiple laboratory shifts.

$VRX {{ '2017-07-17T14:04:54+0000' | timeago}} • Announcement

$VRX has entered into an agreement to sell its Obagi Medical Products business for $190MM in cash to Haitong International Zhonghua Finance Acquisition Fund I, L.P. The transaction is expected to close in second half of 2017. $VRX intends to use the proceeds from the sale to permanently repay term loan debt under its Senior Secured Credit Facility.

$LIVN {{ '2017-07-12T12:45:32+0000' | timeago}} • Announcement

$LIVN appointed Keyna Skeffington as SVP and General Counsel. Skeffington most recently served as Vice President of Legal – Corporate and Securities, Deputy General Counsel and Assistant Secretary at $MDT.

$VAR {{ '2017-07-11T12:14:17+0000' | timeago}} • Announcement

$VAR begins advanced breast cancer treatments using Edge radiosurgery system in combination with respiratory gating. The Edge radiosurgery system enables clinicians to attack tumors from outside the body using carefully shaped high-energy X-rays.

$MDT {{ '2017-07-10T15:43:07+0000' | timeago}} • Announcement

$MDT announced the expanded FDA approval of the self-expanding CoreValve Evolut transcatheter aortic valve replacement platform to include patients with symptomatic severe aortic stenosis who are at an intermediate risk for open-heart surgery.

$VRX {{ '2017-07-10T13:27:06+0000' | timeago}} • Announcement

$VRX pays down $811MM of senior secured term loans using the net proceeds of the sale of Dendreon Pharmaceuticals LLC. The company has now reduced its debt by more than $4.3Bil since the end of 1Q16. $VRX still expects to pay down $5Bil in debt from divestiture proceeds and free cash flow within 18 months of August 2016.

$MTD {{ '2017-07-05T13:49:43+0000' | timeago}} • Announcement

$MTD said Elisha Finney has been appointed to its BoD and Audit Committee, effective November 1, 2017. It is anticipated that Finney will succeed Francis Contino as the Chair of the Audit Committee upon his retirement in May 2018. Finney served as the CFO of $VAR.

$VAR {{ '2017-06-29T13:48:54+0000' | timeago}} • Announcement

$VAR has received both FDA 510(k) clearance and CE mark for its Halcyon system, the company's new device for cancer treatment.

$VAR {{ '2017-06-29T13:28:06+0000' | timeago}} • Announcement

$VAR said it received FDA clearance for its cancer treatment device Halcyon, which enhances image-guided volumetric intensity modulated radiotherapy. The system is designed to accelerate installation timeframes, expedite commissioning and automate treatment.

$MDT {{ '2017-06-23T12:04:14+0000' | timeago}} • Announcement

$MDT has announced a 7% increase in its quarterly cash dividend, raising the amount to $0.46 per ordinary share. The dividend is payable on July 26, 2017, to shareholders of record as of July 7, 2017.

$VAR {{ '2017-06-22T15:41:36+0000' | timeago}} • Announcement

$VAR delivered the cyclotron, a particle accelerator which accelerates protons to two-thirds the speed of light for clinical use, to UK's Christie Proton Therapy Center.

$VAR {{ '2017-06-21T12:39:55+0000' | timeago}} • Announcement

$VAR said it is working with Sify Technologies to provide software-as-a-service (SaaS) to radiotherapy centers across India. The innovative service is being implemented as part of a multi-million dollar investment in treatment equipment and software across Cancer Treatment Services International network of cancer hospitals in India and South Asia.

$HOLX {{ '2017-06-20T15:15:28+0000' | timeago}} • Announcement

$HOLX has obtained FDA clearance to market the Aptima Herpes Simplex Virus (HSV) 1 & 2 molecular assay on the fully automated Panther system. The test will be commercially available in the 50 United States, US territories and Puerto Rico.

$LGND {{ '2017-06-20T13:57:42+0000' | timeago}} • Announcement

$LGND's partner Melinta Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved the delafloxacin drug Baxdela, indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria.

$MDT {{ '2017-06-20T13:54:51+0000' | timeago}} • Announcement

$MDT said data from a recent study showed that its cardiac resynchronization therapy devices reduced healthcare system costs and improved therapy delivery in heart failure patients. A European health-economic analysis indicated that Medtronic’s AdaptivCRT extended life expectancy of patients by about four months, while lowering healthcare costs.

$LGND {{ '2017-06-20T13:19:53+0000' | timeago}} • Announcement

$LGND's partner Melinta Therapeutics said the FDA has approved Baxdela (delafloxacin), indicated in adults for the treatment of acute bacterial skin and skin structure infections caused by susceptible bacteria.

$MDT {{ '2017-06-19T11:01:15+0000' | timeago}} • Announcement

$MDT said its Reactive ATP therapy slows the progression of atrial fibrillation (AF) in patients with implanted cardiac devices. A robust, real-world analysis of nearly 8,800 patients was presented as a late breaking clinical trial at EHRA Europace-Cardiostim 2017.

$HOLX {{ '2017-06-15T13:06:41+0000' | timeago}} • Announcement

$HOLX said that the FDA has granted an expanded clearance for Cynosure's body contouring product, SculpSure, to treat the back and inner and outer thighs. The SculpSure treatment is already FDA-cleared for treatment of the abdomen and love handles.

$LAKE {{ '2017-06-14T20:25:27+0000' | timeago}} • Announcement

$LAKE reported a rise in its 1Q18 profit, mainly due to higher sales volume and continuous cost containment effort. Net income rose to $1.7MM from nominal net income of $3,000 during 1Q17. Diluted EPS rose to $0.23 from $0.00 in 1Q17. Net sales during the quarter rose 12.7% to $23MM versus $20.4MM during prior year period.

$LGND {{ '2017-06-01T16:46:36+0000' | timeago}} • Announcement

$LGND entered into a worldwide license agreement with Cambridge, Massachusetts-based Surface Oncology. Surface will be able to use the OmniRat, OmniMouse and OmniFlic platforms to discover fully human mono- and bispecific antibodies. Surface will be responsible for all costs related to the programs.

Recent Transcripts

PHG (Koninklijke Philips N.V)
Monday, July 24 2017 - 8:00am
LAKE (Lakeland Industries Inc.)
Wednesday, June 14 2017 - 8:30pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
ELMD (Electromed, Inc.)
Tuesday, May 16 2017 - 1:00pm
ETRM (EnteroMedics Inc.)
Tuesday, May 16 2017 - 12:30pm
HOLX (Hologic Inc.)
Wednesday, May 10 2017 - 8:30pm
LGND (Ligand Pharmaceuticals Incorporated)
Tuesday, May 9 2017 - 8:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
KITE (Kite Pharma, Inc.)
Monday, May 8 2017 - 12:30pm
LHCG (LHC Group, Inc.)
Thursday, May 4 2017 - 3:00pm
IRIX (IRIDEX Corporation)
Wednesday, May 3 2017 - 9:30pm
LXRX (Lexicon Pharmaceuticals, Inc.)
Tuesday, May 2 2017 - 10:00pm
CUTR (Cutera, Inc.)
Monday, May 1 2017 - 9:00pm
LMNX (Luminex Corporation)
Monday, May 1 2017 - 8:30pm
DRAD (Digirad Corporation)
Friday, April 28 2017 - 3:00pm
LPNT (LifePoint Health, Inc.)
Friday, April 28 2017 - 2:00pm
LMAT (LeMaitre Vascular, Inc.)
Wednesday, April 26 2017 - 9:00pm
VAR (Varian Medical Systems, Inc.)
Wednesday, April 26 2017 - 9:00pm
LAKE (Lakeland Industries Inc.)
Wednesday, April 26 2017 - 8:30pm
PHG (Koninklijke Philips N.V)
Monday, April 24 2017 - 8:00am

AlphaGraphics you may like